{"id":"NCT01076088","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)","officialTitle":"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial in China to Study the Safety and Efficacy of Co-administration of Sitagliptin and Metformin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-11-15","primaryCompletion":"2012-12-24","completion":"2012-12-24","firstPosted":"2010-02-25","resultsPosted":"2014-02-06","lastUpdate":"2017-05-23"},"enrollment":744,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Sitagliptin 50 mg","otherNames":["Januvia®, Tesavel®, Xelevia®, Ristaben®"]},{"type":"DRUG","name":"Metformin 500 mg","otherNames":["Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®"]},{"type":"DRUG","name":"Sitagliptin 100 mg","otherNames":["Januvia®, Tesavel®, Xelevia®, Ristaben®"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Metformin 850 mg","otherNames":["Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®"]}],"arms":[{"label":"Sitagliptin 50 mg + metformin 500 mg","type":"EXPERIMENTAL"},{"label":"Sitagliptin 50 mg + metformin 850 mg","type":"EXPERIMENTAL"},{"label":"Metformin 500 mg","type":"ACTIVE_COMPARATOR"},{"label":"Metformin 850 mg","type":"ACTIVE_COMPARATOR"},{"label":"Sitagliptin 100 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will assess the efficacy and safety of initial treatment with sitagliptin and metformin in patients with type 2 diabetes mellitus in China. The primary hypothesis is that after 24 weeks, initial co-administration treatment with sitagliptin and metformin provided greater reduction in hemoglobin A1C (A1C) compared to initial treatment with sitagliptin alone and with metformin alone.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1C (A1C) at Week 24","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Sitagliptin 50 mg + Metformin 500 mg","deltaMin":-1.67,"sd":null},{"arm":"Sitagliptin 50 mg + Metformin 850 mg","deltaMin":-1.83,"sd":null},{"arm":"Metformin 500 mg","deltaMin":-1.29,"sd":null},{"arm":"Metformin 850 mg","deltaMin":-1.56,"sd":null},{"arm":"Sitagliptin 100 mg","deltaMin":-0.99,"sd":null},{"arm":"Placebo","deltaMin":-0.59,"sd":null}],"pValues":[{"comp":"OG001 vs OG003","p":"0.087"},{"comp":"OG001 vs OG004","p":"<0.001"},{"comp":"OG000 vs OG002","p":"0.014"},{"comp":"OG000 vs OG004","p":"<0.001"},{"comp":"OG001 vs OG005","p":"<0.001"},{"comp":"OG003 vs OG005","p":"<0.001"},{"comp":"OG000 vs OG005","p":"<0.001"},{"comp":"OG002 vs OG005","p":"<0.001"},{"comp":"OG004 vs OG005","p":"0.011"},{"comp":"OG001 vs OG003","p":"0.008"},{"comp":"OG001 vs OG004","p":"<0.001"},{"comp":"OG000 vs OG002","p":"0.007"},{"comp":"OG000 vs OG004","p":"<0.001"},{"comp":"OG001 vs OG005","p":"<0.001"},{"comp":"OG003 vs OG005","p":"<0.001"},{"comp":"OG000 vs OG005","p":"<0.001"},{"comp":"OG002 vs OG005","p":"<0.001"},{"comp":"OG004 vs OG005","p":"0.004"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["27181998"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":122},"commonTop":["Diarrhoea","Hypoglycaemia","Nausea"]}}